Expertise in
24
conditions

Dr. Jennifer Valerin

Hematology
UCI Health
101 The City Dr S, 
Orange, CA 
Offers Telehealth
Expertise in
24
conditions
UCI Health
101 The City Dr S, 
Orange, CA 

Overview

Jennifer Valerin is a Hematologist in Orange, California. Dr. Valerin is highly rated in 24 conditions, according to our data. Her top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Melanoma, and Rhabdoid Tumor Predisposition Syndrome.

Her clinical research consists of co-authoring 17 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in TX

Hospital Affiliations

Uci Health-Orange

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

UCI Health
101 The City Dr S, Orange, CA 92868
Other Locations
UCI Health Chao Family Comprehensive Cancer Center and Ambulatory Care
19208 Jamboree Rd, Irvine, CA 92612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other, Drug
Study Drugs: Dabrafenib, Navitoclax, Trametinib
Study Phase: Phase 1/Phase 2
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
View 4 Less Clinical Trials

17 Total Publications

Patterns of immune-related adverse events in patients treated for various cancer types with immune checkpoint inhibitors.
Patterns of immune-related adverse events in patients treated for various cancer types with immune checkpoint inhibitors.
Journal: Future oncology (London, England)
Published: December 21, 2025
Similar Doctors
Expertise in
30
conditions
Dr. Lauren Pinter
Hematology
Expertise in
30
conditions
Dr. Lauren Pinter
Hematology

Office

101 The City Dr S Bldg 23, 
Orange, CA 
 (0.8 miles away)
714-456-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lauren Pinter is a Hematologist in Orange, California. Dr. Pinter is highly rated in 30 conditions, according to our data. Her top areas of expertise are T-Cell Lymphoma, Mycosis Fungoides, Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Expertise in
22
conditions
Dr. Stefan Ciurea
Hematology
Expertise in
22
conditions
Dr. Stefan Ciurea
Hematology

UCI Health

101 The City Dr S, 
Orange, CA 
 (0.1 miles away)
714-880-7812
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stefan Ciurea is a Hematologist in Orange, California. Dr. Ciurea is highly rated in 22 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
13
conditions
Dr. Misako Nagasaka
Hematology
Expertise in
13
conditions
Dr. Misako Nagasaka
Hematology

UCI Health

101 The City Dr S, 
Orange, CA 
 (0.1 miles away)
714-456-7002
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Misako Nagasaka is a Hematologist in Orange, California. Dr. Nagasaka is highly rated in 13 conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Gastrostomy.

Frequently Asked Questions about Dr. Jennifer Valerin

How do I make an appointment with Dr. Jennifer Valerin?

You can book an appointment with Dr. Jennifer Valerin by calling their office at 714-456-7002. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jennifer Valerin a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jennifer Valerin is classified as an Distinguished expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jennifer Valerin specialize in?

While Dr. Jennifer Valerin is a Hematology, they have specific expertise in Pancreatic Cancer, Familial Pancreatic Cancer, and Melanoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jennifer Valerin participate in research or clinical trials?

Yes. Dr. Jennifer Valerin has published 17 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Jennifer Valerin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jennifer Valerin accept my insurance?

Dr. Jennifer Valerin accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 714-456-7002 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Valerin's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile